Abstract
Topical administration is attractive and non-invasive gene delivery approach. It is simple and allows repeated administration. In addition, the skin is active immune surveillance site. Topical gene therapy, although promising for treatment of cancer, dermatological disorders, vaccination and autoimmune disease, has not progressed yet to clinical trials. The inability of nucleic acids to survive the extraand intracellular environment and to permeate through the outermost layer of the skin, the stratum corneum, compromise the therapeutic outcomes of nucleic acids-based therapies. Nanostructured vehicles (e.g. transfersomes, niosomes, nanoemulsions, gemini-lipid nanoparticles and biphasic vesicles) have the ability to partially disrupt and perturb lipids that are found in the skin layers and deliver their nucleic acid cargos to their targeted subcellular compartments. However, the efficiency of these carriers is still inferior to other invasive methods (e.g. epidermal and intradermal injections). The goal of this review is to examine the critical parameters required to enhance the efficiency of the currently available nanostructured vehicles, for example, by combining them with minimally invasive techniques, such as, electroporation, iontophoresis, microneedles, ultrasound, gene gun and femtosecond laser. The recent advances in engineering these nanovectors will be discussed with a focus on their future prospects.
Keywords: Gene therapy, topical delivery, transdermal delivery, permeation enhancers, non-viral vectors, transfersomes, niosomes, nanoemulsions, biphasic vesicles, gemini-lipid nanoparticles.
Current Pharmaceutical Design
Title:Needle-free Gene Delivery Through the Skin: An Overview of Recent Strategies
Volume: 19 Issue: 41
Author(s): Mahmoud Elsabahy and Marianna Foldvari
Affiliation:
Keywords: Gene therapy, topical delivery, transdermal delivery, permeation enhancers, non-viral vectors, transfersomes, niosomes, nanoemulsions, biphasic vesicles, gemini-lipid nanoparticles.
Abstract: Topical administration is attractive and non-invasive gene delivery approach. It is simple and allows repeated administration. In addition, the skin is active immune surveillance site. Topical gene therapy, although promising for treatment of cancer, dermatological disorders, vaccination and autoimmune disease, has not progressed yet to clinical trials. The inability of nucleic acids to survive the extraand intracellular environment and to permeate through the outermost layer of the skin, the stratum corneum, compromise the therapeutic outcomes of nucleic acids-based therapies. Nanostructured vehicles (e.g. transfersomes, niosomes, nanoemulsions, gemini-lipid nanoparticles and biphasic vesicles) have the ability to partially disrupt and perturb lipids that are found in the skin layers and deliver their nucleic acid cargos to their targeted subcellular compartments. However, the efficiency of these carriers is still inferior to other invasive methods (e.g. epidermal and intradermal injections). The goal of this review is to examine the critical parameters required to enhance the efficiency of the currently available nanostructured vehicles, for example, by combining them with minimally invasive techniques, such as, electroporation, iontophoresis, microneedles, ultrasound, gene gun and femtosecond laser. The recent advances in engineering these nanovectors will be discussed with a focus on their future prospects.
Export Options
About this article
Cite this article as:
Elsabahy Mahmoud and Foldvari Marianna, Needle-free Gene Delivery Through the Skin: An Overview of Recent Strategies, Current Pharmaceutical Design 2013; 19 (41) . https://dx.doi.org/10.2174/13816128113199990369
DOI https://dx.doi.org/10.2174/13816128113199990369 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Interleukin-25: Key Regulator of Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Generation of Regulatory T Cells to Antigen Expressed in the Retina
Current Immunology Reviews (Discontinued) Vitiligo in Children: A Birds Eye View
Current Pediatric Reviews Biologics as Treatment for Systemic Lupus: Great Efforts, Sobering Results, New Challenges
Current Drug Discovery Technologies Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology Structure, Function and Biological Relevance of Prolyl Oligopeptidase
Current Protein & Peptide Science Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Current Pharmaceutical Design Cholecystokinin-8 and Nerve Growth Factor: two Endogenous Molecules Working for the Upkeep and Repair of the Nervous System
Current Drug Targets - CNS & Neurological Disorders Regulation of the PI3K-Akt Network: Current Status and a Promise for the Treatment of Human Diseases
Current Signal Transduction Therapy Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Current Pharmaceutical Design NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets The Yin and Yang of Non-Neuronal α7-Nicotinic Receptors in Inflammation and Autoimmunity
Current Drug Targets The Relationship Between Social Support, Social Constraint, and Psychological Adjustment for Patients with Rare Autoimmune Disease
Current Rheumatology Reviews Cellular and Molecular Mechanisms Involved in the Action of Vitamin D Analogs Targeting Vitiligo Depigmentation
Current Drug Targets Regulatory T Cells in Severe Drug Eruptions
Current Immunology Reviews (Discontinued) Immune Aging and Autoimmune Diseases in Children
Current Immunology Reviews (Discontinued) Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmunity in Type 1 Diabetes
Current Stem Cell Research & Therapy